ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms
ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms
复制标题
DOI：
10.1158/1055-9965.epi-20-1581
复制
发表时间：
2021-05-01
影响因子：
3.8
通讯作者：
Koike, Kazuhiko
中科院分区：
文献类型：
--
作者：
Hamada, Tsuyoshi;Oyama, Hiroki;Koike, Kazuhiko
背景：ABO血型与多种恶性肿瘤的风险有关，包括胰腺癌。没有研究评估ABO血型与导管内乳头状粘液性肿瘤（IPMN）患者随访期间胰腺癌发生率的相关性。方法：在1994年至2019年东京大学（日本东京）诊断为胰腺囊肿的3，164例患者中，我们确定了1，815例IPMN患者的ABO血型数据。我们研究了ABO血型与胰腺癌发病率的关系，总体上和按癌症类型[IPMN衍生的癌或伴随的胰腺导管腺癌（PDAC）]。利用竞争风险比例风险模型，我们估计子分布风险比（SHR）的胰腺癌的发病率与调整潜在的混杂因素，包括囊肿characteristics.Results：在11,518人年的后续行动，我们确定了97例诊断为胰腺癌（53与IPMN衍生癌和44伴随PDAC）。与O型血型患者相比，A型、B型和AB型血型患者的胰腺癌多变量SHR（95%置信区间）分别为2.25（1.25-4.07; P = 0.007）、2.09（1.08-4.05; P = 0.028）和1.17（0.43-3.19; P = 0.76）。我们观察到ABO血型与胰腺癌发病率的癌types.Conclusions：在这个大型的长期研究中，与血型A或B的IPMN患者出现胰腺癌的风险较高相比，与O型血的影响：ABO血型可以与IPMN患者的胰腺癌风险的生物标志物。
Background: ABO blood group has been associated with risks of various malignancies, including pancreatic cancer. No study has evaluated the association of ABO blood group with incidence of pancreatic carcinogenesis during follow-up of patients with intraductal papillary mucinous neoplasms (IPMN).Methods: Among 3,164 patients diagnosed with pancreatic cysts at the University of Tokyo (Tokyo, Japan) from 1994 through 2019, we identified 1,815 patients with IPMN with available data on ABO blood group. We studied the association of ABO blood group with incidence of pancreatic carcinoma, overall and by carcinoma types [IPMN-derived carcinoma or concomitant pancreatic ductal adenocarcinoma (PDAC)]. Utilizing competing-risks proportional hazards models, we estimated subdistribution hazard ratios (SHR) for incidence of pancreatic carcinoma with adjustment for potential confounders, including cyst characteristics.Results: During 11,518 person-years of follow-up, we identified 97 patients diagnosed with pancreatic carcinoma (53 with IPMN-derived carcinoma and 44 with concomitant PDAC). Compared with patients with blood group O, patients with blood groups A, B, and AB had multivariable SHRs (95% confidence intervals) for pancreatic carcinoma of 2.25 (1.25-4.07; P = 0.007), 2.09 (1.08-4.05; P = 0.028), and 1.17 (0.43-3.19; P = 0.76), respectively. We observed no differential association of ABO blood group with pancreatic carcinoma incidence by carcinoma types.Conclusions: In this large long-term study, patients with IPMN with blood group A or B appeared to be at higher risk of pancreatic carcinoma compared with those with blood group O.Impact: ABO blood group can be a biomarker for pancreatic cancer risk among patients with IPMNs.